The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.
Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.
The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.
Alnylam's RNAi TTR Silencing Drug Amvuttra FDA Approved for Transthyretin Amyloidosis Cardiomyopathy
The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.
The firm's LLM-based platform abstracted complex information from medical charts with up to 100 percent accuracy in a pilot study of breast cancer patients.
The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.
The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.
An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.
Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times ...
The firm's stock price dropped 27 percent on Tuesday following the news that the young man died from acute liver failure after getting Elevidys.
In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback